The pharmaceutical industry invests heavily in technologies—$57.4 billion in 2022 alone—to discover new therapies to treat our greatest health challenges. Yet drug development teams are still using the same antiquated, manual processes to move those life-changing therapies toward commercialization.

The program recognizes innovative New Jersey companies and individuals for excellence and leadership in digital technology fields. SciMar ONE is proud to be making a difference in the NJ technology community through our efforts to accelerate drug development.

SciMar ONE chosen for Merck Digital Sciences Studio. The collaboration is focused on improving Development Velocity™.

By Donna Conroy, MS, published in Clinical Researcher

Development Velocity is the speed a pharmaceutical company moves a therapy through the development process and into the market.

SciMar ONE was named semi-finalist on Pepperdine Graziadio Business School’s Most Fundable Companies list.

SciMar ONE and CEO Donna Conroy were featured by MedCity News in a preview of the healthcare startups competing at HLTH 2022.

2022 HLTH Startup Pitch Competition Roundup SciMar was featured by Health IT Answers as one of the 12 participants chosen among hundred for the 2022 HLTH Startup Pitch Competition.  Read the full article here:   HLTH Startup Pitch Competition – Health IT Answers

SciMar ONE chosen for the 2022 HLTH Startup Pitch Competition. CEO Donna Conroy, MS, will share how SciMar’s DV Platform™ accelerates drug development.

Drug development is a complex, intricate and multilayered process. The question pharma needs to evaluate is: Is it helping or further complicating the development process if multiple siloed technologies are being adopted and then manually stitched together?

SciMar ONE’s AI platform, The Scientific Data Engine® is available as a transactable offer in Microsoft’s Azure Marketplace!